SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
PacificHealth Laboratories, Inc.
--------------------------------
(Name of Issuer)
Common Stock, $.0025 par value
------------------------------
(Title of Class of Securities)
695113 10 0
--------------
(CUSIP Number)
Stephen P. Kuchen, Executive Vice President
1480 Route 9 North, Suite 204
Woodbridge, NJ 07095
732/636-6141
-------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
Copies to:
Joseph Chicco, Esquire
Eckert Seamans Cherin & Mellott, LLC
1515 Market Street - 9th Floor
Philadelphia, PA
215/851-8410
June 13, 2000
-------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
<PAGE>
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
-------------------------------------------------------------------------------
1 | NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSONS
|
| Robert Portman
-------------------------------------------------------------------------------
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
| (See Instructions) (a) |_|
| (b) |_|
--------------------------------------------------------------------------------
3 | SEC USE ONLY
|
|
--------------------------------------------------------------------------------
4 | SOURCE OF FUNDS (see Instructions)
|
| 00 (No funds required)
--------------------------------------------------------------------------------
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
| TO ITEMS 3(d) OR 2(e)
| Not Applicable
--------------------------------------------------------------------------------
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
|
| USA (New Jersey)
--------------------------------------------------------------------------------
| 7 | SOLE VOTING POWER
| |
| | 744,767 shares
NUMBER OF SHARES |-----|--------------------------------------
BENEFICIALLY | 8 | SHARED VOTING POWER
OWNED BY EACH | |
REPORTING PERSON | | -0-
WITH |-----|--------------------------------------
| 9 | SOLE DISPOSITIVE POWER
| |
| | 744,767 shares
|-----|--------------------------------------
| 10 | SHARED DISPOSITIVE POWER
| |
| | -0-
--------------------------------------------------------------------------------
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
| 1,761,434 shares of Common Stock including 1,016,667 shares issuable
| upon the exercise of presently exercisable options
--------------------------------------------------------------------------------
12 | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
| SHARES (See Instructions)
| |X|
--------------------------------------------------------------------------------
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
| 31.2%
--------------------------------------------------------------------------------
14 | TYPE OF REPORTING PERSON (see Instructions)
|
| IN
--------------------------------------------------------------------------------
ii
<PAGE>
ITEM 1. SECURITY AND ISSUER.
This statement on Schedule 13D/A (this "Statement") relates to the common
stock, $.0025 par value (the "Common Stock") of PacificHealth Laboratories, Inc.
(the "Issuer"), 1480 Route 9 North, Suite 204, Woodbridge, NJ 07095.
ITEM 2. IDENTITY AND BACKGROUND.
(a) - (b) Robert Portman
188 Igoe Road
Morganville, NJ 07751
(c) President and Chief Executive Officer
PacificHealth Laboratories, Inc.
1480 Route 9 North, Suite 204
Woodbridge, NJ 07095
(d) None
(e) None
(f) USA (New Jersey)
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
No funds were involved. This Statement relates to the grant of options to
purchase Common Stock under the Issuer's 1995 Incentive Stock Option Plan.
ITEM 4. PURPOSE OF TRANSACTION.
Compensation and incentive to Mr. Portman.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
Robert Portman's interests in securities of the issuer as of the date of
this Statement are as follows:
(a) (i) Common Stock:
744,767 shares owned directly
200,000 shares owned by Robert Portman's spouse, as to which
beneficial ownership is disclaimed
1
<PAGE>
(ii) Options to buy Common Stock:
Presently exercisable options to purchase 1,016,667 shares, as
follows:
Expiration
# of Shares Exercise Price Date
----------- -------------- ----------
225,000 $3.75 3/31/2000
316,667 $6.00 1/1/2003
200,000 $2.25 3/2/2004
275,000 $2.50 6/1/2005
-------
1,016,667
Additional options to purchase Common Stock which are not
presently exercisable, as follows:
<TABLE>
<CAPTION>
No. of Date First Exercise Expiration
Shares Exercisable Price Date
------- ----------- -------- ----------
<S> <C> <C> <C>
100,000 11/4/2000 $1.75 11/4/2004
158,333 1/1/2001 $6.00 1/1/2003
-------
258,333
</TABLE>
(b) Robert Portman has the sole power to vote and dispose of 744,767 shares
owned directly, and will have sole power to vote and dispose of all shares
issuable upon the exercise of options.
Robert Portman's spouse has the sole power to vote and dispose of 200,000
shares owned by Mrs. Portman.
(c) Recent transactions:
(i) 4/30/2000 - previously outstanding options to purchase 300,000
shares at $2.00/share expired
(ii) 6/13/2000 - options to purchase 275,000 shares at $2.50 per share
granted under the Issuer's 1995 Incentive Stock Option Plan
2
<PAGE>
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER.
None.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
None.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
PacificHealth Laboratories, Inc.
/s/ Robert Portman
------------------
ROBERT PORTMAN
Title President
---------------------
Dated June 21, 2000
---------------------
